Conformis, Inc. (CFMS)
| Market Cap | 118.92M |
| Revenue (ttm) | 101.13M |
| Net Income (ttm) | 6.94M |
| Shares Out | 186.10M |
| EPS (ttm) | 0.05 |
| PE Ratio | 14.20 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 716,731 |
| Open | 0.665 |
| Previous Close | 0.668 |
| Day's Range | 0.635 - 0.687 |
| 52-Week Range | 0.635 - 1.955 |
| Beta | 1.30 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+213.0%) |
| Earnings Date | Nov 3, 2021 |
About CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee; and iTotal Identity, a knee system. It also provides Conformis Hip System and Cordera h...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for Conformis stock is "Strong Buy." The 12-month stock price forecast is 2.00, which is an increase of 212.99% from the latest price.
News
Conformis, Inc. to Provide Business Update and Initial Expectations for 2022 on January 6, 2022
BILLERICA, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will provide a business update and initial expectations for 2022 before the market opens on Thu...
Conformis, Inc. Announces Departure of Chief Legal Officer, Corporate Secretary
BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will...
Conformis, Inc. Appoints James Paiva as its new Vice President of U.S. Marketing; Inducement Grant Reported
BILLERICA, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that the Company has appointed James Paiva as its new Vice President, U.S. Marketing.
ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates
ConforMIS (CFMS) delivered earnings and revenue surprises of 0.00% and 1.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Conformis Reports Third Quarter 2021 Financial Results
BILLERICA, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today fina...
ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
Conformis, Inc. to Release Third Quarter 2021 Financial Results on November 3, 2021
BILLERICA, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the third quarter ended September 30, 2021 after the mar...
Conformis (CFMS) Sees Hammer Chart Pattern: Time to Buy?
Conformis (CFMS) has been struggling lately, but the selling pressure may be coming to an end soon.
Conformis Posts Clinical Study Data For Its Knee Implants
Conformis Inc (NASDAQ: CFMS) announced results of a published retrospective study of procedures using Conformis' patient-specific iTotal CR (cruciate-retaining) knee replacement implant. Data showed tha...
Conformis, Inc. Announces Strong Clinical Study Results for Its Personalized Knee Implants
A retrospective review of 540 procedures performed demonstrated 98.5% Implant Survivorship and 89.0% Patient Satisfaction for the Conformis patient-specific iTotal® CR (cruciate-retaining) knee replacem...
Top Ranked Momentum Stocks to Buy for September 22nd
CROX, GSKY, RRC, and CFMS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 22, 2021
Why Conformis Plummeted by Almost 11% on Wednesday
A cut in revenue guidance didn't make investors happy.
Investors React To Conformis' Annual Sales Guidance Update
Conformis Inc (NASDAQ: CFMS) stock is down after the Q3 revenue update ahead of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. Related Link: Conformis Q2 Earnings Surpass Estimates O...
Conformis, Inc. Provides Business Update
Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Business Update Provided in Advance of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?
Penny Stocks For Your Biotech Watch List In September 2021
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
7 of the Best Penny Stocks for Any Portfolio
As the global economy recovers in fits and starts, one way to play the long-term expansion in global markets is with solid penny stocks. The post 7 of the Best Penny Stocks for Any Portfolio appeared fi...
Conformis, Inc. to Participate in Upcoming Investor Conferences
BILLERICA, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), an orthopedic medical device company that features a range of personalized knee and hip replacement products, announc...
Conformis, Inc. Announces First Procedure Performed Using the Identity Imprint™ Knee Replacement System
BILLERICA, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) today announced the first procedure with the new Conformis Identity Imprint knee replacement system.
Conformis Q2 Earnings Surpass Estimates On Higher Volumes And Royalties, License Revenue
Conformis Inc (NASDAQ: CFMS) Q2 revenues more than doubled to $56.3 million, beating the consensus of $33 million. The increase was driven primarily by elective procedure volumes and royalty & licensing...
ConforMIS (CFMS) Surpasses Q2 Earnings and Revenue Estimates
ConforMIS (CFMS) delivered earnings and revenue surprises of 162.50% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Top Penny Stocks to Watch to Start Your Week Off Right
Which Penny Stocks Are Investors Watching As August Gets Off to a Strong Start? The post Top Penny Stocks to Watch to Start Your Week Off Right appeared first on Penny Stocks to Buy, Picks, News and In...
ConforMIS (CFMS) Earnings Expected to Grow: Should You Buy?
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Penny Stocks to Buy in August? 4 for Your Watchlist
Which penny stocks are investors watching with August only a week away? The post Best Penny Stocks to Buy in August?